• The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
  • Subscribe
  • Sign in
  • Pharma
  • Medtech
  • Biotech
  • Science
  • Events
  • Careers
  • Jobs
  • Opinion & Debate
  • The Magazine
  • Advertising
  • NLS Member
  • About Us
  • Contact
Menu
  • Subscribe
  • Sign in

No 01 2021

QTE Development

-

February 8, 2021

Share article on X
Share article on Linkedin

Updated: January 31, 2025, 09:22 am

Published: February 8, 2021

Top stories

Agreement – May 26, 2026

Oncopeptides signs agreement with Salus

The agreement addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states. Under the terms of the agreement, Salus is granted exclusive rights to market and sell Pepaxti in Slovenia, Croatia, Hungary, Slovakia, the Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, […]

Column – May 26, 2026

A region that grows when we grow together

Every successful region has a place where collaboration is allowed to take root and grow. A place that protects early ideas, carries learning forward, and helps people work together across borders even when the systems around them are not built for it. In Medicon Valley, many now share a simple vision: to create a kind of greenhouse for Nordic life science cooperation.

Financing – May 26, 2026

Spago Nanomedical resolves on a rights issue of approximately SEK 16 million

The Board of Directors of Spago Nanomedical has resolved on a new issue of shares with preferential rights for the company’s existing shareholders of approximately SEK 16 million before issue costs.

Clinical Trials – May 25, 2026

Sobi announces positive Phase 3 results

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Follow NLS news
Follow us on XFollow us on LinkedinFollow us on Bluesky

Related posts

Agreement - May 26, 2026

Oncopeptides signs agreement with Salus

The agreement addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states. Under the terms of the agreement, Salus is granted exclusive rights to market and sell Pepaxti in Slovenia, Croatia, Hungary, Slovakia, the Czech Republic, Poland, Bulgaria, Romania, Lithuania, Latvia, […]

Column - May 26, 2026

A region that grows when we grow together

Every successful region has a place where collaboration is allowed to take root and grow. A place that protects early ideas, carries learning forward, and helps people work together across borders even when the systems around them are not built for it. In Medicon Valley, many now share a simple vision: to create a kind of greenhouse for Nordic life science cooperation.

Financing - May 26, 2026

Spago Nanomedical resolves on a rights issue of approximately SEK 16 million

The Board of Directors of Spago Nanomedical has resolved on a new issue of shares with preferential rights for the company’s existing shareholders of approximately SEK 16 million before issue costs.

Clinical Trials - May 25, 2026

Sobi announces positive Phase 3 results

Sobi has announced positive topline results from the pivotal Phase 3 REDUCE 2 study evaluating pozdeutinurad (AR882), an investigational next-generation once-daily oral selective URAT1 inhibitor, in adults with gout including those with uncontrolled gout (also referred to as progressive gout) and inadequately controlled by existing therapies.

Financing - May 22, 2026

Neobiomics receives investment from HealthCap

The company has announced an investment led by HealthCap, and conjunction with this capital infusion, Neobiomics strengthens its board with the appointment of a new director, Mårten Steen, Managing Partner at HealthCap. 

Collaboration - May 20, 2026

Western Sweden unites to boost life sciences competitiveness

Industry, academic, and public stakeholders will join forces in a new council aimed at accelerating the region's life science development.

Clinical Trials - May 20, 2026

Oncopeptides secures regulatory approval to start Window-of-Opportunity study

Oncopeptides' clinical trial application for the "Window-of-Opportunity" (WoO) study in glioblastoma has been formally approved in Norway.

Sign up to our Newsletter!

I confirm that I want to subscribe to newsletters from Nordic Life Science and that Nordic Life Science has the right to save my email address. Read our privacy policy here

Read the latest issue!

Sign up for a subscription and read our latest digital issue today.

Sign up
Sign up

The leading life science news channel in the Nordic region.

© NLS Media Group AB – All rights reserved

Digital and print
  • The magazine
  • Subscribe
  • Newsletter
More information
  • About us
  • Contact
  • Advertising
Social media
  • LinkedIn
  • Bluesky
  • X
NLS Media Group AB

St Paulsgatan 13

118 46 Sweden

info@nlsnews.com

+46-8-588 941 51

  • Cookies
  • Data management and privacy policy

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.